Sciele Pharma will pay $29 million in cash for Addrenex Pharmaceuticals, in a transaction which builds on a series of product licensing deals between the two US firms over the past few years.
The immediate benefits for Sciele, itself acquired by Shionogi for $1.4 billion just over a year ago, include access to...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
